PSMA PET Radiotracers and Access Barriers in Prostate Cancer

In "PSMA PET Radiotracers and Access Barriers in Prostate Cancer," the panel examines the radiotracers approved for PSMA PET and the practical hurdles to obtaining timely, high-quality scans.

Dr. Ghesani reviews the PSMA PET radiotracers currently available, including gallium-68 PSMA-11, approved in 2020, and two fluorine-18 agents, noting their differing half-lives, sensitivity, and specificity ranges. He explains that all three are renally excreted small molecules, unlike the larger prior-generation SPECT agents that limited earlier PSMA-based imaging efforts. He describes differences in recommended imaging windows across agents and notes that fluorine-based tracers are typically cyclotron-produced, while gallium relies primarily on a generator-based supply chain. Dr. Ghesani then asks the panelists about access barriers related to availability, scheduling, reimbursement, and geography. Dr. Yonover describes practicing in a large urban market with abundant academic and hospital resources, but explains that his group built its own in-house molecular imaging capability to improve scheduling and standardize image quality across serial scans. He notes ongoing reimbursement friction, particularly when carriers demand a rising PSA before approving PSMA PET in patients with radiographic progression but stable biochemistry, and in patients with PTEN-deficient disease who may need more frequent imaging. Dr. Mendel describes a starkly different environment in El Paso, where the nearest cyclotron is hundreds of miles away, forcing reliance on gallium generators. He explains that his practice ultimately built its own theragnostic center, including a PET unit, therapy bays, and an in-house radiopharmacy, to control quality and scheduling rather than sending patients to inconsistent outside facilities. Dr. Yonover adds that having a generator on-site insulates practices from supply-chain disruptions and enables more reliable serial scanning on the same equipment and camera. Dr. Mendel describes ongoing reimbursement battles, noting that PSMA agents and radioligand therapies are expensive enough that an unpaid claim can be financially damaging for an independent practice, though he expects the modality's use to keep expanding as clinicians increasingly recognize imaging-based progression without corresponding PSA change.

Our next episode, "Adjudicating Indeterminate Bone Lesions in Prostate Cancer Imaging," turns to one of the most vexing scenarios in molecular imaging: the indeterminate bone lesion.